Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ambarella Inc (AMBA) vs Viatris Inc (VTRS) Price & Performance

Ambarella IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Ambarella Inc vs Viatris Inc — how do they compare? Ambarella Inc trades at $74.98 (market cap $3.39B), while Viatris Inc trades at $16.36 (market cap $18.94B). The key difference: Viatris Inc is far larger — about 5.6× Ambarella Inc's market cap, and Viatris Inc pays a 2.95% dividend while Ambarella Inc pays none. Which is the better fit depends on your goals.

AMBAVTRS
Market Cap
$3.39B$18.94B
Sector
TechnologyHealth
52-Week High
$95.51$17.39
52-Week Low
$48.65$8.74
Enterprise Value
$3.13B$31.15B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ambarella Inc

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

Viatris Inc

Viatris (VTRS) trades at $16.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has beaten EPS estimates for the last three quarters, though it reported a net loss of $3.51B in 2025. Revenue has declined from $16.3B in 2022 to $14.3B in 2025. Positive news includes FDA acceptance of a new drug application for fast-acting meloxicam and a Phase 3 study success for VR-205, targeting a Japanese NDA by end of 2026.

The outlook is mixed: analyst consensus is a $20 price target with a 'Hold' bias, but high debt and negative margins pose risks. Upside potential hinges on pipeline success and debt reduction, while competitive pressures and execution challenges remain key concerns for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ambarella Inc

Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.

Read more on AMBA

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS